Clinical Trial Update: Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thalidomide plus rituximab in Waldenström's macroglobulinemia has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoplasmacytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Rituxan (rituximab)
• Thalomid (thalidomide)

Snippet

Sponsor: Steven P. Treon, MD, PhD | Conditions: Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-02